Total (n = 346) | DOAC (n = 74) | Vitamin K antagonist (n = 272) | p | ||||
---|---|---|---|---|---|---|---|
Age, [median (IQR)] | 78.0 | (70–84) | 77.0 | (69–82) | 79.0 | (72–84) | 0.064 |
Gender (male) | 199 | (57.5) | 45 | (60.8) | 154 | (56.6) | 0.518 |
Comorbidities | |||||||
Hypertension | 146 | (42.2) | 30 | (40.5) | 116 | (42.6) | 0.745 |
Diabetes | 63 | (18.2) | 10 | (13.5) | 53 | (19.5) | 0.238 |
Peripheral arterial disease | 26 | (7.5) | 6 | (8.1) | 20 | (7.4) | 0.827 |
Hypertensive cardiopathy | 75 | (21.7) | 17 | (23.0) | 58 | (21.3) | 0.760 |
Coronary heart disease | 91 | (26.3) | 14 | (18.9) | 77 | (28.3) | 0.104 |
Valvular cardiopathy | 75 | (21.7) | 15 | (20.3) | 60 | (22.1) | 0.741 |
Chronic kidney disease | 99 | (28.6) | 25 | (33.8) | 74 | (27.2) | 0.267 |
Liver insufficiency | 6 | (1.7) | 2 | (2.7) | 4 | (1.5) | 0.472 |
COPD | 21 | (6.1) | 6 | (8.1) | 15 | (5.5) | 0.407 |
Venous thromboembolism | 61 | (17.6) | 11 | (14.9) | 50 | (18.4) | 0.481 |
Aortic disease | 15 | (4.3) | 3 | (4.1) | 12 | (4.4) | 0.893 |
Stroke | 48 | (13.9) | 9 | (12.2) | 39 | (14.3) | 0.631 |
Carcinoma | 37 | (10.7) | 16 | (21.6) | 21 | (7.7) | 0.001 |
Coagulopathy | 13 | (3.8) | 1 | (1.4) | 12 | (4.4) | 0.220 |